Budget impact model of a 5-grass sublingual immunotherapy tablet for the treatment of grass pollen-induced allergic rhinitis.

Abstract:

OBJECTIVE:Allergic rhinitis (AR) is a chronic disease with a substantial clinical and economic burden. This study estimated the potential budget impact (BI) associated with market entry of Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract Tablet for Sublingual Use ('5-grass SLIT tablet') for patients aged 10-65 with grass pollen-induced AR. METHODS:A budget impact model was constructed to estimate the potential BI from a US payer perspective. The model calculated pharmacy, medical, and total (pharmacy + medical) costs per-member-per-month (PMPM) with and without market entry of the 5-grass SLIT tablet, considering a 3-year time horizon. The target population was determined using an epidemiological approach and existing literature. The treatment market shares without 5-grass SLIT tablet entry were derived from an analysis of de-identified insurance claims data. Pharmacy costs and medical utilization rates and costs were obtained from the claims data analysis and existing literature. One-way sensitivities were conducted for key model inputs. RESULTS:Using an illustrative example of a hypothetical health plan with one million members, the estimated target population of AR patients aged 10-65 was 26,320. On a PMPM basis, pharmacy costs increased by $0.36, $0.44, and $0.51, while total costs (after medical cost offsets) increased by $0.15, $0.18, and $0.22 in the first, second, and third years following entry of the 5-grass SLIT tablet, respectively. Results were most sensitive to changes in the compliance rate, treatment duration, and price. The BI will vary from the base case example when alternative, payer-specific inputs are used. CONCLUSIONS:Using base case inputs, use of the 5-grass SLIT tablet to treat grass pollen-induced AR increased the pharmacy budget for a hypothetical third-party payer. Higher pharmacy costs were partially offset by lower medical budget due to reduced resource use compared with existing treatments.

journal_name

J Med Econ

authors

Ivanova JI,Kelkar S,King S,Birnbaum HG,Hocker S,Phipps R,Lankow R

doi

10.3111/13696998.2015.1061533

subject

Has Abstract

pub_date

2015-01-01 00:00:00

pages

909-18

issue

11

eissn

1369-6998

issn

1941-837X

journal_volume

18

pub_type

杂志文章
  • Budget impact analysis of secukinumab versus adalimumab in the treatment of ankylosing spondylitis.

    abstract:BACKGROUND:Biologic treatments have enhanced the treatment outcomes of patients with active ankylosing spondylitis (AS). Until recently, TNF-alpha-inhibitors have been the only biologics approved for the treatment of active AS. The objective of this study was to assess the potential financial impact of the first non-TN...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2018.1551227

    authors: Purmonen T,Törmälehto S,Wahlman H,Puolakka K

    更新日期:2019-02-01 00:00:00

  • Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.

    abstract:OBJECTIVE:To compare 1-year costs and benefits of dapagliflozin (DAPA), a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, with those of other treatments for type 2 diabetes (T2D), such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), sulfonylureas (SUs), thiazolidinediones (TZDs), and dipeptidyl peptidase-4 ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2018.1434182

    authors: Chakravarty A,Rastogi M,Dhankhar P,Bell KF

    更新日期:2018-05-01 00:00:00

  • Cost of macrovascular complications in people with diabetes from a public healthcare perspective: a retrospective database study in Brazil.

    abstract::Aims: To evaluate costs in patients with diabetes who experienced a macrovascular complication from a Brazilian public healthcare system perspective.Materials and methods: A retrospective, observational study that utilized the database of the Brazilian Unified Health System (DATASUS). Data for direct medical costs (ho...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2020.1764966

    authors: Julian GS,Campos D,Broe Honore J,Sauer Tobaruella F,Hyun Yoon J,Hallén N

    更新日期:2020-09-01 00:00:00

  • The burden of osteoporosis in Saudi Arabia: a scorecard and economic model.

    abstract::Objectives: Aging populations are contributing to an increased volume of osteoporotic fractures. The goals of this study were to (1) develop a scorecard on epidemiological burden, policy framework, service provision, and service uptake for osteoporosis in Saudi Arabia and (2) estimate the direct costs of managing oste...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2020.1737536

    authors: Aziziyeh R,Garcia Perlaza J,Saleem N,Sadat-Ali M,Elsalmawy A,McTavish RK,Duperrouzel C,Cameron C

    更新日期:2020-07-01 00:00:00

  • Ulipristal acetate for pre-operative treatment of moderate-to-severe uterine fibroids in women of reproductive age in The Netherlands: cost minimization analysis and budget impact analysis.

    abstract:OBJECTIVE:Ulipristal acetate has been found to be non-inferior to other pre-operative treatments of uterine fibroids, particularly leuprolide. The objective of this study was to assess the pharmacoeconomic profile of ulipristal acetate compared to leuprolide for the pre-operative treatment of moderate-to-severe uterine...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2016.1254090

    authors: Zakiyah N,van Asselt AD,Postma MJ

    更新日期:2017-03-01 00:00:00

  • Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment.

    abstract:OBJECTIVE:To assess predictors and costs of multiple sclerosis (MS) relapse, a potential outcome measure in payer-manufacturer risk-sharing agreements for disease-modifying drugs (DMDs). METHODS:A retrospective cohort analysis of medical/pharmacy claims was used. Study patients had ≥1 DMD (interferon beta, glatiramer,...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2013.823868

    authors: Lage MJ,Carroll CA,Fairman KA

    更新日期:2013-09-01 00:00:00

  • Similar patient outcomes yet different hospital costs between flowable hemostatic agents.

    abstract:INTRODUCTION:SURGIFLO and FLOSEAL are absorbable gelatin-based products that form hemostatic matrices. These products are indicated as adjuncts to hemostasis when control of bleeding by conventional surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. This study analyzed the effect o...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1044994

    authors: David G,Lim S,Gunnarsson C,Kocharian R,Roy S

    更新日期:2015-01-01 00:00:00

  • Healthcare resource utilization and costs associated with herpes zoster in the US.

    abstract:OBJECTIVES:To evaluate the economic burden of herpes zoster (HZ) on the US healthcare system among an immunocompetent population. METHODS:Claims data from the MarketScan Research databases for 2008-2011 were extracted to determine the incremental healthcare resource utilization (RU) and direct medical costs associated...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2016.1187150

    authors: Johnson BH,Palmer L,Gatwood J,Lenhart G,Kawai K,Acosta CJ

    更新日期:2016-10-01 00:00:00

  • Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv.

    abstract:AIMS:In this pharmacoeconomic simulation, we: (1) modeled the cost-efficiency of converting patients from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv for prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN) from the US payer perspective, (2) simulated how savings enable, on a budget-neutral b...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2020.1833339

    authors: MacDonald K,McBride A,Alrawashdh N,Abraham I

    更新日期:2020-10-24 00:00:00

  • Cost minimization analysis of capecitabine versus 5-fluorouracil-based treatment for gastric cancer patients in Hong Kong.

    abstract:BACKGROUND:EOX (epirubicin, oxaliplatin, Xeloda; capecitabine) and FOLFOX4 (5-fluorouracil (5-FU), leucovorin, oxaliplatin) are the common chemotherapy regimens used in the treatment of advanced gastric cancer (aGC) in Hong Kong. This study aimed to compare the costs of these therapies for aGC patients from both the he...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2017.1296452

    authors: Zhou KR,Cheng A,Ng WT,Kwok TY,Yip EY,Yao R,Leung PY,Lee VW

    更新日期:2017-05-01 00:00:00

  • Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis.

    abstract:OBJECTIVE:To investigate adherence to dornase alfa therapy among commercially-insured patients with cystic fibrosis (CF) and to examine the impact of adherence on health and economic outcomes. METHODS:This retrospective cohort analysis included CF patients with ≥1 dornase alfa (Pulmozyme) pharmacy claim between 1 Octo...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2013.787427

    authors: Nasr SZ,Chou W,Villa KF,Chang E,Broder MS

    更新日期:2013-01-01 00:00:00

  • Treatment cost of non-small cell lung cancer in three European countries: comparisons across France, Germany, and England using administrative databases.

    abstract:INTRODUCTION:Lung cancer is a highly prevalent condition with non-small cell lung cancer (NSCLC), representing ∼ 80%. Given its high prevalence and poor survival rates, it is important to understand costs associated with NSCLC treatment. OBJECTIVES:To carry out an incidence-based study in three European countries: Fra...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1032974

    authors: McGuire A,Martin M,Lenz C,Sollano JA

    更新日期:2015-01-01 00:00:00

  • Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients.

    abstract:AIM:This analysis assessed the direct medical costs of newly-diagnosed, temozolomide (TMZ)-treated glioblastoma (GBM) from the perspective of a US commercial setting. MATERIALS AND METHODS:The analysis included subjects identified from the IMS PharMetrics LifeLink Plus™ claims database from January 1, 2008 to August 3...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2017.1364258

    authors: Jiang S,Hill K,Patel D,Waldeck AR,Botteman M,Aly A,Norden AD

    更新日期:2017-12-01 00:00:00

  • Pilot study assessing the direct medical cost of treating patients with cancer in Kenya; findings and implications for the future.

    abstract:BACKGROUND:Currently the majority of cancer deaths occur in low- and middle-income countries, where there are appreciable funding concerns. In Kenya, most patients currently pay out of pocket for treatment, and those who are insured are generally not covered for the full costs of treatment. This places a considerable b...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2018.1484372

    authors: Atieno OM,Opanga S,Martin A,Kurdi A,Godman B

    更新日期:2018-09-01 00:00:00

  • A modified method for estimating volume-outcome relationships: application to percutaneous coronary intervention.

    abstract:OBJECTIVE:The objective of the current study was to propose an alternative method for measuring individual operator and peer volumes to use as predictors for adverse outcomes. STUDY DESIGN:A retrospective analysis was performed to assess the volume-outcome relationship for percutaneous coronary intervention (PCI) perf...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696990701815578

    authors: Xie Y,Rizzo JA,Brown DL

    更新日期:2008-01-01 00:00:00

  • The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment.

    abstract:OBJECTIVE:To critically evaluate published cost-effectiveness studies of novel drug products requiring less-frequent medication dosing compared to conventional formulations of the same drug substance. METHODS:A search was conducted in the Medline and Embase databases for cost-effectiveness studies published before May...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,评审

    doi:10.3111/13696991003757500

    authors: Cheng MM,Alfonso R,Best JH,Garrison LP,Bruhn D,Veenstra DL

    更新日期:2010-01-01 00:00:00

  • Constructing a value-based healthcare system for hypertensive patients through changing payment mode: evidence from a comparative study in rural China.

    abstract:OBJECTIVE:To construct a value-based healthcare system for rural Chinese hypertensive patients through an increasing outpatient care reimbursement ratio. METHODS:This comparative study sampled two similar counties, Dangyang County and Zhijiang County, in Hubei Province of China, as the intervention group and the contr...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2018.1558864

    authors: Miao Y,Yuan X,Gu J,Zhang L,He R,Sandeep S,Wu J

    更新日期:2019-03-01 00:00:00

  • Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.

    abstract:AIMS:The study compared all-cause and major depressive disorder (MDD)-related healthcare resource use (HRU) and costs in patients with MDD treated with atypical antipsychotic (AAP) adjunctive therapy early or later in treatment. MATERIALS AND METHODS:Adults with MDD and antidepressant treatment (ADT) who newly initiat...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2018.1484373

    authors: Seetasith A,Greene M,Hartry A,Burudpakdee C

    更新日期:2018-09-01 00:00:00

  • A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made availabl

    abstract:BACKGROUND:Validation of overall survival (OS) extrapolations of immune-checkpoint inhibitors (ICIs) during the National Institute for Health and Care Excellence (NICE) Single Technology Assessment (STA) process is limited due to data still maturing at the time of submission. Inaccurate extrapolation may lead to inappr...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,评审

    doi:10.1080/13696998.2018.1547303

    authors: Bullement A,Meng Y,Cooper M,Lee D,Harding TL,O'Regan C,Aguiar-Ibanez R

    更新日期:2019-03-01 00:00:00

  • Healthcare costs among patients with chronic constipation: a retrospective claims analysis in a commercially insured population.

    abstract:OBJECTIVE:To evaluate total annual all-cause, gastrointestinal-related, and symptom-related healthcare costs among chronic constipation (CC) patients and estimate incremental all-cause healthcare costs of CC patients relative to matched controls. METHODS:Patients aged ≥18 years with continuous medical and pharmacy ben...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2013.860375

    authors: Cai Q,Buono JL,Spalding WM,Sarocco P,Tan H,Stephenson JJ,Carson RT,Doshi JA

    更新日期:2014-02-01 00:00:00

  • Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: comparison between 6-month and 3-month depot formulations.

    abstract:AIMS:This study aimed to evaluate the economic value for leuprorelin acetate 6-month depot compared with leuprorelin acetate 3-month depot from a societal perspective in Japanese prostate cancer patients. METHODS:The cost analysis estimated the reduction in direct and indirect costs as well as intangible costs saved b...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2017.1362410

    authors: Goto R,Uda A,Hiroi S,Iwasaki K,Takashima K,Oya M

    更新日期:2017-11-01 00:00:00

  • Adapting a global cost-effectiveness model to local country requirements: posaconazole case study.

    abstract:BACKGROUND:Many countries have various requirements for local economic analyses to assess the value of a new health technology and/or to secure reimbursement. This study presents a case study of an economic model developed to assess the cost-effectiveness of posaconazole vs standard azole therapy (fluconazole/itraconaz...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.761633

    authors: Papadopoulos G,Hunt S,Prasad M

    更新日期:2013-01-01 00:00:00

  • Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians).

    abstract:OBJECTIVE:To characterize patient and physician satisfaction with current standard-of-care botulinum toxin treatment regimens for symptom control in patients with post-stroke spasticity using structured interviews with patients and physicians. RESEARCH DESIGN AND METHODS:Two cross-sectional surveys were conducted in C...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2014.925462

    authors: Bensmail D,Hanschmann A,Wissel J

    更新日期:2014-09-01 00:00:00

  • Chronic noncancer pain intensity is inversely related to analgesic adherence in pain clinics.

    abstract:OBJECTIVE:The relationship between chronic noncancer pain (CNCP) control and pain medication (analgesic) adherence has not been widely documented. The primary aim of this study was to evaluate the relationship between pain intensity and the degree of adherence to analgesic medication prescribed in pain clinics. There w...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2011.598202

    authors: Stern A,Sánchez-Magro I,Rull M

    更新日期:2011-01-01 00:00:00

  • Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands.

    abstract:BACKGROUND:Until recently, standard treatment of venous thromboembolism (VTE) concerned a combination of short-term low-molecular-weight heparin (LMWH) and long-term vitamin-K antagonist (VKA). Risk of bleeding and the requirement for regular anticoagulation monitoring are, however, limiting their use. Rivaroxaban is a...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/13696998.2017.1331912

    authors: Heisen M,Treur MJ,Heemstra HE,Giesen EBW,Postma MJ

    更新日期:2017-08-01 00:00:00

  • Cost-effectiveness analysis of oxycodone with naloxone versus oxycodone alone for the management of moderate-to-severe pain in patients with opioid-induced constipation in Canada.

    abstract:BACKGROUND:Approximately 20-30% of Canadians suffer from chronic pain. Guidelines for the management of chronic pain support the use of controlled-release (CR) opioids to treat chronic pain. Although effective in managing chronic pain, oxycodone is associated with high rates of opioid-induced constipation (OIC). The co...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1116992

    authors: Goeree R,Goeree J

    更新日期:2016-01-01 00:00:00

  • The economic burden associated with SSRI treatment failure in a managed care population.

    abstract:OBJECTIVE:The objective of this study was to describe the economic burden to managed care associated with failure of selective serotonin reuptake inhibitor (SSRI) therapy in terms of direct medical costs. METHODS:A retrospective analysis of the PharMetrics database, a national managed care medical and pharmacy claims ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696990802522339

    authors: Balkrishnan R,Joish VN,Yang T,Jayawant SS,Mullins CD

    更新日期:2008-01-01 00:00:00

  • Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation in the Japanese healthcare setting.

    abstract::Aims: This article aimed to examine the cost-effectiveness of rivaroxaban in comparison to warfarin for stroke prevention in Japanese patients with non-valvular atrial fibrillation (NVAF), from a public healthcare payer's perspective.Materials and methods: Baseline event risks were obtained from the J-ROCKET AF trial ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2019.1688821

    authors: Hori M,Tanahashi N,Akiyama S,Kiyabu G,Dorey J,Goto R

    更新日期:2020-03-01 00:00:00

  • Long-term health-related burden of adult congenital heart diseases in Hong Kong.

    abstract::Aims: This study aimed to examine the long-term clinical and economic burden of adults with congenital heart disease (ACHD) in Hong Kong. Methods: It retrospectively analyzed 336 consecutive ACHD patients who attended the Adult Congenital Heart Clinic between January 1, 2009 and December 31, 2014. Direct medical costs...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2019.1613239

    authors: Lee VWY,Yan BP,Fong TMC,Fung AKP,Cheng FWT

    更新日期:2019-08-01 00:00:00

  • Pricing methods in outcome-based contracting: integration analysis of the six dimensions (6 δs).

    abstract:AIMS:Six Delta is a six-dimensional independent platform for outcome-based pricing/contracting. The six dimensions have been described separately: (δ1) cost-effectiveness analysis and cost-utility analysis-based pricing; (δ2) willingness-to-pay-based pricing; (δ3) reference-based pricing; (δ4) safety-based pricing; (δ5...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2020.1815031

    authors: Alkhatib NS,McBride A,Slack M,Bhattacharjee S,Erstad B,Ramos K,Abraham I

    更新日期:2020-11-01 00:00:00